Clinical efficacy of intracavernous injection of platelet lysate for erectile dysfunction

Abstract Background Among the emerging treatments for erectile dysfunction (ED), platelet-rich plasma (PRP), known for its ability to enhance tissue repair and regeneration, stands out as a promising therapeutic approach. In this innovative study, we aimed to assess the efficacy of intracavernous in...

Full description

Saved in:
Bibliographic Details
Main Authors: Yi-Kai Chang, I-Ni Chiang, Hong-Chiang Chang, Yi-Hui Chen, Shih-Chieh Jeff Chueh
Format: Article
Language:English
Published: BMC 2024-10-01
Series:BMC Urology
Subjects:
Online Access:https://doi.org/10.1186/s12894-024-01633-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850179548836003840
author Yi-Kai Chang
I-Ni Chiang
Hong-Chiang Chang
Yi-Hui Chen
Shih-Chieh Jeff Chueh
author_facet Yi-Kai Chang
I-Ni Chiang
Hong-Chiang Chang
Yi-Hui Chen
Shih-Chieh Jeff Chueh
author_sort Yi-Kai Chang
collection DOAJ
description Abstract Background Among the emerging treatments for erectile dysfunction (ED), platelet-rich plasma (PRP), known for its ability to enhance tissue repair and regeneration, stands out as a promising therapeutic approach. In this innovative study, we aimed to assess the efficacy of intracavernous injections of platelet lysate (PL), a derivative of PRP, in improving erectile function among ED patients. Methods We enrolled twenty-six patients, aged between 35 and 70 years (mean age 51.6 ± 11.3 years), who had been experiencing ED for over six months and had an International Index of Erectile Function-5 (IIEF-5) score of 21 or less. Participants received autologous PL injections intracavernously every two weeks for a total of five administrations. We assessed Erection Hardness Score (EHS) and International Index of Erectile Function-5 (IIEF-5) bi-weekly for 16 weeks and conducted penile Doppler ultrasounds pre- and post-treatment to record peak systolic velocity (PSV) and resistance index (RI). Results Before treatment, the mean EHS was 2.15 ± 0.88 and IIEF-5 was 10.92 ± 5.28. Remarkable improvements were observed post-treatment, with the EHS significantly increasing to 3.15 ± 0.83 (p < 0.05) and IIEF-5 to 17.23 ± 5.26 (p < 0.05). Penile Doppler ultrasound exhibited an increase in both PSV and RI post-treatment, with the rise in RI being statistically significant. Conclusions Our findings indicate that intracavernous injections of PL substantially enhance erectile function, as evidenced by improvements in EHS, IIEF-5, and the RI of penile Doppler ultrasound, without hemorrhagic events or other adverse reactions apart from temporary pain at the injection site during the 16-week follow-up period. These encouraging results suggest that PL injections are a safe and effective treatment modality for patients with moderate ED, potentially providing a less invasive and more physiologically friendly alternative to current ED management strategies. Trial registration The study received approval from the Institutional Review Board of National Taiwan University Hospital (IRB Number 202008061RIPC, date of registration 08/28/2020).
format Article
id doaj-art-5a207b413ba342c990daee83224d26e9
institution OA Journals
issn 1471-2490
language English
publishDate 2024-10-01
publisher BMC
record_format Article
series BMC Urology
spelling doaj-art-5a207b413ba342c990daee83224d26e92025-08-20T02:18:28ZengBMCBMC Urology1471-24902024-10-012411910.1186/s12894-024-01633-2Clinical efficacy of intracavernous injection of platelet lysate for erectile dysfunctionYi-Kai Chang0I-Ni Chiang1Hong-Chiang Chang2Yi-Hui Chen3Shih-Chieh Jeff Chueh4Department of Urology, College of Medicine, National Taiwan University Hospital, National Taiwan UniversityDepartment of Urology, College of Medicine, National Taiwan University Hospital, National Taiwan UniversityDepartment of Urology, College of Medicine, National Taiwan University Hospital, National Taiwan UniversityCollege of Medicine, National Taiwan University Hospital, National Taiwan UniversityDepartment of Urology, College of Medicine, National Taiwan University Hospital, National Taiwan UniversityAbstract Background Among the emerging treatments for erectile dysfunction (ED), platelet-rich plasma (PRP), known for its ability to enhance tissue repair and regeneration, stands out as a promising therapeutic approach. In this innovative study, we aimed to assess the efficacy of intracavernous injections of platelet lysate (PL), a derivative of PRP, in improving erectile function among ED patients. Methods We enrolled twenty-six patients, aged between 35 and 70 years (mean age 51.6 ± 11.3 years), who had been experiencing ED for over six months and had an International Index of Erectile Function-5 (IIEF-5) score of 21 or less. Participants received autologous PL injections intracavernously every two weeks for a total of five administrations. We assessed Erection Hardness Score (EHS) and International Index of Erectile Function-5 (IIEF-5) bi-weekly for 16 weeks and conducted penile Doppler ultrasounds pre- and post-treatment to record peak systolic velocity (PSV) and resistance index (RI). Results Before treatment, the mean EHS was 2.15 ± 0.88 and IIEF-5 was 10.92 ± 5.28. Remarkable improvements were observed post-treatment, with the EHS significantly increasing to 3.15 ± 0.83 (p < 0.05) and IIEF-5 to 17.23 ± 5.26 (p < 0.05). Penile Doppler ultrasound exhibited an increase in both PSV and RI post-treatment, with the rise in RI being statistically significant. Conclusions Our findings indicate that intracavernous injections of PL substantially enhance erectile function, as evidenced by improvements in EHS, IIEF-5, and the RI of penile Doppler ultrasound, without hemorrhagic events or other adverse reactions apart from temporary pain at the injection site during the 16-week follow-up period. These encouraging results suggest that PL injections are a safe and effective treatment modality for patients with moderate ED, potentially providing a less invasive and more physiologically friendly alternative to current ED management strategies. Trial registration The study received approval from the Institutional Review Board of National Taiwan University Hospital (IRB Number 202008061RIPC, date of registration 08/28/2020).https://doi.org/10.1186/s12894-024-01633-2Erectile dysfunctionPlatelet-rich plasmaPlatelet lysateIntracavernous injection
spellingShingle Yi-Kai Chang
I-Ni Chiang
Hong-Chiang Chang
Yi-Hui Chen
Shih-Chieh Jeff Chueh
Clinical efficacy of intracavernous injection of platelet lysate for erectile dysfunction
BMC Urology
Erectile dysfunction
Platelet-rich plasma
Platelet lysate
Intracavernous injection
title Clinical efficacy of intracavernous injection of platelet lysate for erectile dysfunction
title_full Clinical efficacy of intracavernous injection of platelet lysate for erectile dysfunction
title_fullStr Clinical efficacy of intracavernous injection of platelet lysate for erectile dysfunction
title_full_unstemmed Clinical efficacy of intracavernous injection of platelet lysate for erectile dysfunction
title_short Clinical efficacy of intracavernous injection of platelet lysate for erectile dysfunction
title_sort clinical efficacy of intracavernous injection of platelet lysate for erectile dysfunction
topic Erectile dysfunction
Platelet-rich plasma
Platelet lysate
Intracavernous injection
url https://doi.org/10.1186/s12894-024-01633-2
work_keys_str_mv AT yikaichang clinicalefficacyofintracavernousinjectionofplateletlysateforerectiledysfunction
AT inichiang clinicalefficacyofintracavernousinjectionofplateletlysateforerectiledysfunction
AT hongchiangchang clinicalefficacyofintracavernousinjectionofplateletlysateforerectiledysfunction
AT yihuichen clinicalefficacyofintracavernousinjectionofplateletlysateforerectiledysfunction
AT shihchiehjeffchueh clinicalefficacyofintracavernousinjectionofplateletlysateforerectiledysfunction